Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for prevention of antibody-mediated rejection in desensitized living donor kidney transplant recipients
2010-019630-28Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of eculizumab in humoral rejection (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Primary safety and efficacy endpoint: prevention of AMR post-transplant. Started Jun 2011; status: terminated.
02
Drugs
eculizumab
03
Conditions
humoral rejection
Beyond the preview
Go deeper on 2010-019630-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019630-28.